Table 2. Comparison between refractory patients and relapsed patients.

HL characteristics at diagnosis	Record for	Refractory patients, n= 11	Relapsed patients, n= 47	p
General characteristics
Female, n (%)	58	6 (54.6 %)	23 (49.0 %)	1.00
Age at HL diagnosis (years), median [IQR]	58	20.9 [19.6 – 22.6]	21.1 [18.9 – 23.1]	0.97
Ann Arbor stage, n (%)	58			0.51
Stages I and II		3 (27.3 %)	19 (40.4 %)
Stages III and IV		8 (72.7 %)	28 (59.6 %)
ECOG performance status, n (%)	55			0.43
0		6 (60 %)	34 (75.6 %)
>= 1		4 (40 %)	11 (24.4 %)
Histologic subtype, n (%)	58			0.41
Nodular sclerosis		8 (72.7 %)	35 (74.5 %)
Mixed cellularity		2 (18.2 %)	11 (23.4 %)
Lymphocyte predominance		0	1 (2.1 %)
Unclassified		1 (9.1 %)	0
LMP staining, n (%)	28			1.00
Positive		0	4 (16 %)
Negative		3 (100 %)	21 (84 %)
Nodal involvement
Mediastinal involvement, n (%)	58			0.11
Absent		0	4 (8.9 %)
Present		5 (45.4 %)	32 (68.0 %)
Bulky disease		6 (54.6 %)	11 (23.4 %)
Extra-nodal involvement
Extra-nodal involvement	54	4 (44.4 %)	18 (40 %)	1.00
Lung	57	3 (27.3 %)	12 (26.1 %)	1.00
Pericardia	55	1 (10.0 %)	4 (8.9 %)	1.00
Pleura	56	0	7 (15.6 %)	0.32
Biological characteristics
Hemoglobin (g/dl), median [IQR]	40	11.3 [10.2 – 12.3]	12.3 [11.1 – 13.0]	0.24
Leukocytes (G/l), median [IQR]	34	17.3 [10.2 – 29.5]	11.0 [9.5 – 14.9]	0.20
Albumin (g/dl), median [IQR]	25	38.0 [34.0 – 38.0]	38.5 [31.8 – 43.0]	0.71
Lymphocytes (% of white cell count), median [IQR]	30	10.0 [8.3 – 12.5]	12.5 [9.5 – 15.0]	0.48
Lactate dehydrogenase (above normal range), %	35	2 (33.3 %)	15 (51.7 %)	0.66
Autologous stem cell transplantation, n (%)	57	10 (90.9 %)	37 (78.7 %)
Double		3 (27.3 %)	4 (8.5 %)
Allogeneic stem cell transplantation, n (%)		0	7 (14.9 %)
Overall survival at 5 years, % [95%CI]	58	21.2 % [6.3-71.6]	77.9 % [66.7-91.0]	<0.01§

§ log rank test.